Published in PLoS One on February 03, 2016
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (1987) 17.08
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Alzheimer's disease. N Engl J Med (2010) 13.13
Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology (2002) 7.73
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Translating cell biology into therapeutic advances in Alzheimer's disease. Nature (1999) 5.42
Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (2006) 3.74
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc Natl Acad Sci U S A (1988) 2.95
The dementias. Lancet (2002) 2.42
Identification of D-peptide ligands through mirror-image phage display. Science (1996) 2.12
Soluble Aβ oligomer production and toxicity. J Neurochem (2011) 1.83
Amyloid-beta aggregation. Neurodegener Dis (2007) 1.57
Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J (2008) 1.52
Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol (2010) 1.33
Aβ oligomer-induced synapse degeneration in Alzheimer's disease. Cell Mol Neurobiol (2011) 1.33
D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc Natl Acad Sci U S A (2010) 1.29
Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proc Natl Acad Sci U S A (2005) 1.28
Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. Biochem J (2000) 1.23
Gamma secretase inhibitors of Notch signaling. Onco Targets Ther (2013) 1.21
Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways. J Biol Chem (2010) 1.20
Size-dependent neurotoxicity of beta-amyloid oligomers. Arch Biochem Biophys (2010) 1.17
Physiochemical characterization of the Alzheimer's disease-related peptides A beta 1-42Arctic and A beta 1-42wt. FEBS J (2006) 1.14
D-peptides as immunogens and diagnostic reagents. Curr Opin Biotechnol (1998) 1.11
Atomic force microscopy and MD simulations reveal pore-like structures of all-D-enantiomer of Alzheimer's β-amyloid peptide: relevance to the ion channel mechanism of AD pathology. J Phys Chem B (2012) 1.11
Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. Biochim Biophys Acta (2007) 1.11
Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Biochemistry (2010) 1.11
Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. J Clin Pharm Ther (2013) 1.08
Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J Neurobiol (1999) 1.05
Reduction of Alzheimer's disease amyloid plaque load in transgenic mice by D3, A D-enantiomeric peptide identified by mirror image phage display. ChemMedChem (2008) 1.04
Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice. ACS Chem Neurosci (2010) 0.98
β-Amyloid oligomers in aging and Alzheimer's disease. Front Aging Neurosci (2013) 0.98
A kinetic aggregation assay allowing selective and sensitive amyloid-β quantification in cells and tissues. Biochemistry (2011) 0.94
In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models. ChemMedChem (2009) 0.93
Different roles of D-amino acids in immune phenomena. FASEB J (1997) 0.93
Amyloid-β(1-42) protofibrils formed in modified artificial cerebrospinal fluid bind and activate microglia. J Neuroimmune Pharmacol (2012) 0.89
Design, synthesis, and evaluation of resveratrol derivatives as Aß(₁-₄₂) aggregation inhibitors, antioxidants, and neuroprotective agents. Bioorg Med Chem Lett (2012) 0.88
Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. Angew Chem Int Ed Engl (2015) 0.88
Prion-like Mechanisms in Alzheimer's Disease. Curr Alzheimer Res (2014) 0.87
Mirror-image phage display: aiming at the mirror. Chembiochem (2003) 0.85
Mirror image phage display--a method to generate D-peptide ligands for use in diagnostic or therapeutical applications. Mol Biosyst (2009) 0.85
Keampferol-3-O-rhamnoside abrogates amyloid beta toxicity by modulating monomers and remodeling oligomers and fibrils to non-toxic aggregates. J Biomed Sci (2012) 0.84
Prevention of Alzheimer's disease-associated Abeta aggregation by rationally designed nonpeptidic beta-sheet ligands. J Biol Chem (2004) 0.84
QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers. Sci Rep (2015) 0.82
Mirror image phage display--generating stable therapeutically and diagnostically active peptides with biotechnological means. J Biotechnol (2012) 0.80
Molecular mimics of the tumour antigen MUC1. PLoS One (2012) 0.80
Competitively selected protein ligands pay their increase in specificity by a decrease in affinity. Mol Biosyst (2009) 0.80
[Clinical diagnosis and therapeutic possibilities for dementia of the Alzheimer type]. Fortschr Neurol Psychiatr (1994) 0.78
Discovery of γ-secretase modulators with a novel activity profile by text-based virtual screening. ACS Chem Biol (2012) 0.77